Avitas Wealth Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Avitas Wealth Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,484	Closed	-$405K	–	218
2021 Q1	$405K	Sell	5,484 -1,093	-17%	-$82.7K	0.08%	190
2020 Q4	$461K	Buy	6,577 +1,561	+31%	+$98.8K	0.09%	189
2020 Q3	$284K	Buy	5,016 +25	+0.5%	+$1.47K	0.08%	174
2020 Q2	$291K	Sell	4,991 -24	-0.5%	-$1.31K	0.1%	154
2020 Q1	$233K	Sell	5,015 -1,494	-23%	-$77.9K	0.11%	125
2019 Q4	$364K	Sell	6,509 -59	-0.9%	-$3.08K	0.09%	154
2019 Q3	$311K	Buy	6,568 +2,444	+59%	+$125K	0.09%	160
2019 Q2	$221K	Buy	4,124 +90	+2%	+$4.67K	0.06%	162
2019 Q1	$223K	Buy	+4,034	New	+$213K	0.06%	157

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACM

Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

PSUF

People's United Financial Bridgeport, Connecticut $3.51B AUM 12.24% 1-Year Est. Return

Avitas Wealth Management's PBE Position: Q2 2021 in Review

Avitas Wealth Management sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2021, closing a stake of 5,484 shares — an estimated $405K sold.

Avitas Wealth Management first reported a position in PBE in Q1 2019 and held it in 9 quarters. The position peaked at $461K in Q4 2020. 94 funds tracked by Wall St. Rank hold PBE as of Q2 2021.

Avitas Wealth Management reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2021 after selling out during the quarter.
Avitas Wealth Management sold 5,484 Invesco Biotechnology & Genome ETF shares in Q2 2021, an estimated $405K.
Avitas Wealth Management first reported a position in Invesco Biotechnology & Genome ETF in Q1 2019 and held it in 9 quarters.
Avitas Wealth Management's Invesco Biotechnology & Genome ETF position peaked at $461K in Q4 2020.
94 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2021.

Based on Avitas Wealth Management's 13F filing for Q2 2021, filed 12 Jul 2021.